Threshold Pharmaceuticals (THLD)
Threshold Pharmaceuticals Market Cap: 369.47M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
THLD Market Cap Rankings
| Overall | 44th percentile | 2567 of 4665 |
| Sector | 58th percentile | 217 of 527 in Healthcare |
| Industry | 68th percentile | 51 of 164 in Biotechnology |
THLD Market Cap Range, Past 5 Years
| Minimum | 3.562M | Dec 2008 |
| Maximum | 453.46M | Mar 2012 |
| Average | 74.72M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these THLD related companies
THLD News
$THLD http://stks.co/43kr Watch break of $7.50; Nice volume over last few sessions
about 9 hours ago by amitp_gupta
about 9 hours ago by amitp_gupta
@reuvenohr love this one long for past 5-6 months now, steamy Hot! $THLD
about 13 hours ago by HighGrowthFinancial
about 13 hours ago by HighGrowthFinancial
RT @HighGrowthFinancial $THLD buying pressure<-discussing it now in webinar
about 13 hours ago by reuvenohr
about 13 hours ago by reuvenohr
$THLD we are right at resistance we need to push little higher, or lose the war, The upper channel always tough to break. Check the chart
about 18 hours ago by woowtrading
about 18 hours ago by woowtrading
maybey play $ARIA $GALE $THLD strangle hold for ASCO over the weekend/next week for fun
about 22 hours ago by johnkelly
about 22 hours ago by johnkelly
$thld conference on june 6th. Regardless of whether it can be a catalyst or not, it will provide us with news about TH-302. Long.
about 23 hours ago by Akasbari111
about 23 hours ago by Akasbari111
♥ Market Wrap Video + Additions to Watch List http://stks.co/42wS including: $ARNA, $THLD $IN $CBOU $LPSN
about a day ago by StockTiger
about a day ago by StockTiger
RT @StockTiger Market Wrap Video + Additions to Watch List http://stks.co/42lt including: $ARNA, $THLD $IN $CBOU $LPSN
about a day ago by sssc
about a day ago by sssc
$THLD my stock pick for next month. Valauable to day traders like myself, but also great for long term investors..WATCH THIS STOCK
about a day ago by SirPerfluous
about a day ago by SirPerfluous
$THLD invest in this company now look for it to rise by the middle of 2013 message me for explanatio
about a day ago by SirPerfluous
about a day ago by SirPerfluous
$THLD about to soar in 2013, current cancer prevention research in motion
about a day ago by SirPerfluous
about a day ago by SirPerfluous
$REGN a few years ago was worth looking at...i implore you to watch $THLD!!!
about a day ago by SirPerfluous
about a day ago by SirPerfluous
Market Wrap Video + Additions to Watch List http://stks.co/42ZH including: $ARNA, $THLD $IN $CBOU $LPSN
about 2 days ago by StockTiger
about 2 days ago by StockTiger
Threshold Pharmaceuticals Announces Presentation and Webcast at Jefferies Global Healthcare Conference
May 30, 7:30AM Marketwire
May 30, 7:30AM Marketwire
Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational Results
May 03, 4:27PM Marketwire
May 03, 4:27PM Marketwire
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Apr 25, 7:30AM Marketwire
Apr 25, 7:30AM Marketwire
Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference
Apr 13, 7:30AM Marketwire
Apr 13, 7:30AM Marketwire
Threshold Pharmaceuticals (THLD) Reports Positive Phase 2b Trial of TH-302 in Pancreatic Cancer
Mar 30, 4:14PM Street Insider
Mar 30, 4:14PM Street Insider
Threshold (THLD) receives orphan drug status for TH-302 for the treatment of soft tissue sarcoma
Mar 30, 7:33AM Street Insider
Mar 30, 7:33AM Street Insider
Threshold (THLD) at 5-Year High on Analyst PT Boost, Ahead of TH-302 Presentations
Mar 29, 10:51AM Street Insider
Mar 29, 10:51AM Street Insider
Threshold Pharmaceuticals (THLD) Higher After Lazard Capital More Than Doubles Price Target
Mar 29, 8:38AM Street Insider
Mar 29, 8:38AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| THLD | 7.17 | -0.16 | -2.18% | 377.71M |
| THI | 52.16 | -1.14 | -2.14% | 8.441B |
| THG | 38.54 | -0.47 | -1.20% | 1.756B |
| SWM | 65.53 | -1.37 | -2.05% | 1.066B |
| SWKS | 26.11 | -0.75 | -2.79% | 5.061B |
| SWK | 64.46 | -1.79 | -2.70% | 11.29B |
| SWIR | 8.90 | -0.08 | -0.89% | 278.11M |
| SWI | 44.20 | -1.66 | -3.62% | 3.322B |
| SWHC | 6.53 | -0.21 | -3.12% | 437.22M |
| SWC | 8.44 | -0.05 | -0.59% | 981.78M |